Search

Displaying results 2141 - 2150 of 10000 in total
  1. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death.

    Synonyms: N-Carbamyl-L-glutamate, L-N-Carbamoylglutamic acid
  2. Drug

    Mexazolam

    go.drugbank.com/drugs/DB15489
    Investigational

    [A184910] The use of benzodiazepines in the treatment of anxiety is generally a second line measure.[A184910] … Mexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions.

  3. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. … This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  4. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous … Cell Carcinoma of the Head and Neck- GALAXIES H&N-202).

  5. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 … Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered

    Categories: Antivirals used in combination for the treatment of HIV infections
  6. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    It is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.

  7. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. … Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    Ceftobiprole medocaril is a prodrug of [ceftobiprole], a fifth-generation semisynthetic cephalosporin antibacterial. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European

    Products: Zevtera 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
  9. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE. … [L39190] Severe hypoglycemia is an acute, life-threatening medical condition resulting from a profound drop in blood glucose levels.

  10. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. … As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

    Products: AMBRISEN 1A PHARMA 5MG, AMBRISENTAN AL 5MG FTA